KONSYL PHARMACEUTICALS, INC. – Trademark Portfolio
Entity Type: 03
KONSYL PHARMACEUTICALS, INC. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 6 trademarks are registered and 1 is pending. Notable registered marks include KONSYL, SITZMARKS, and SENNA PROMPT. The owner is based in Easton, MD.
8050 Industrial Park Road
Easton, MD 21601
Showing of trademarks Trademarks
Trademark Classifications
KONSYL PHARMACEUTICALS, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does KONSYL PHARMACEUTICALS, INC. have?
KONSYL PHARMACEUTICALS, INC. has 9 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 pending, 2 abandoned.
What trademark classes does KONSYL PHARMACEUTICALS, INC. file in?
KONSYL PHARMACEUTICALS, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 21 (Housewares). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are KONSYL PHARMACEUTICALS, INC.'s most well-known trademarks?
KONSYL PHARMACEUTICALS, INC.'s registered trademark portfolio includes well-known marks such as KONSYL, SITZMARKS, and SENNA PROMPT. These are among 6 currently registered trademarks in the portfolio.
What is KONSYL PHARMACEUTICALS, INC.'s trademark registration success rate?
KONSYL PHARMACEUTICALS, INC. has a 75% trademark registration rate, with 6 out of 8 resolved applications resulting in successful registration. Currently, 1 application is pending review.